Hayashi Kazuhiko, Imaizumi Toshihide, Uchida Kazumi, Kuramochi Hidekazu, Takasaki Ken
Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Shinjuku, Tokyo 162-8666, Japan.
Oncol Rep. 2002 Nov-Dec;9(6):1355-61.
S-1 is a newly developed oral fluoropyrimidine derivative with demonstrated activity against several tumor types. The aim of this study was to evaluate the feasibility and efficacy of S-1 administered as a single-agent and in combination with cisplatin, for the treatment of patients with pancreatic cancer. A total of 33 patients with locally advanced or recurrent pancreatic cancer were entered into this study. Seventeen patients were treated with S-1 alone (group A), and 16 patients were treated with S-1 plus weekly cisplatin (group B). Objective tumor responses among the 15 evaluable patients in group A were 1 CR, 2 PR, 9 SD and 3 PD, and among the 14 evaluable patients in group B were 8 PR, 5 SD, and 1 PD. The overall response rates were 20.0% and 57.1% in groups A and B respectively. Seven of the 17 patients in group A with elevated CA19-9 serum concentration and 12 of the 13 patients in group B with elevated CA19-9 level, reduced their CA19-9 by more than 50%. The median follow-up periods/median durations of response were 152/102 days in group A and 105/66 days in group B. Median survivals have not been reached in either group. In group A, no patient developed severe toxicities over grade 3, but in group B, 3 patients developed hematotoxicity over grade 3, and 2 patients experienced grade 3 anorexia. S-1, especially in combination with CDDP, shows promising activity with acceptable toxicities against pancreatic cancer. Further evaluation of this combination in patients with this disease is warranted.
S-1是一种新开发的口服氟嘧啶衍生物，已证明对多种肿瘤类型具有活性。本研究的目的是评估S-1单药治疗及与顺铂联合治疗胰腺癌患者的可行性和疗效。共有33例局部晚期或复发性胰腺癌患者进入本研究。17例患者接受单纯S-1治疗（A组），16例患者接受S-1加每周一次顺铂治疗（B组）。A组15例可评估患者的客观肿瘤反应为1例完全缓解（CR）、2例部分缓解（PR）、9例疾病稳定（SD）和3例疾病进展（PD），B组14例可评估患者的客观肿瘤反应为8例PR、5例SD和1例PD。A组和B组的总缓解率分别为20.0%和57.1%。A组17例CA19-9血清浓度升高的患者中有7例、B组13例CA19-9水平升高的患者中有12例，其CA19-9降低超过50%。A组的中位随访期/中位反应持续时间为152/102天，B组为105/66天。两组均未达到中位生存期。A组无患者出现3级以上严重毒性，但B组有3例患者出现3级以上血液毒性，2例患者出现3级厌食。S-1，尤其是与顺铂联合使用时，对胰腺癌显示出有前景的活性且毒性可接受。有必要对该联合方案在这种疾病患者中进行进一步评估。
